BioSpace News Archive

These data from the recently completed monotherapy dose-escalation component of the Phase I/Ib study demonstrated that IPI-549 dosed once daily (QD) was well tolerated and clinically active.

Quotient Clinical announces its renaming to Quotient Sciences (Quotient), following the acquisitions of Co-Formulate, QS Pharma and SeaView Research.

Valeant will use approximately $180M of the net proceeds from the sale to repay term loan debt under its Senior Credit Facility.

Net revenues totaled $17.6M, an increase of 2.1%, versus the third quarter of 2016 of $17.2M.

Positive Opinion Based on Five Studies Demonstrating Nplate Reduces Rates of Bleeding in Children With Rare Blood Disorder [10-November-2017] THOUSAND OAKS, Calif., Nov. 10, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opini

In other countries, Vertex will begin the country-by-country reimbursement process following Marketing Authorization.

Second Sight Medical Products announced that the Argus II Retinal Prosthesis System (“Argus II”) has been recommended for public funding by the Ontario Health Technology Advisory Committee (OHTAC) of Health Quality Ontario.

The company is introducing the new feature with the latest LENSAR Laser System upgrade.

The IoT is set to become the next growth driver for the semiconductor industry, as demand for internet-connected devices continues to soar.

With this acquisition, Cambrooke gains access to Ajinomoto’s global nutrition and ingredient sciences expertise, as well as proven flavor and texture-enhancing R&D capabilities.